London, United Kingdom, August 17, 2018 --(PR.com
)-- SMi’s Immuno-Oncology Conference is set to take place this year in London, UK on the 26th and 27th September. The two-day conference will be providing delegates with the unrivalled learning opportunity of hearing from internationally renowned expert speakers giving their expertise and experiences in the ever-evolving field of immuno-oncology.
This year’s Chair has been announced as Dr James Legg, Vice President of Research & Development at Crescendo Biologics Ltd, who will be opening and closing the conference, as well as giving a presentation of his own. Dr Legg is currently Vice President of Research and Development at Crescendo Biologics Ltd in Cambridge, UK, where he is responsible for Crescendo's growing portfolio of Immuno Oncology Humabody Biologics.
Prior to joining Crescendo, James completed a Ph.D. in Molecular Cell Biology at Imperial College London, as well as a Post Doc at Imperial Cancer Research Fund (now CRUK), before moving into the Biotechnology industry with a role at Cambridge Antibody Technology, and taking over a number of positions within MedImmune, the Biologics arm of AstraZeneca.
Snapshot of Chair’s Letter of Invitation:
“Immuno-oncology (IO) is a fast-paced and exciting area of medicine with the potential to deliver highly beneficial and durable cancer therapies for patients. Recent years have seen an exponential increase in the positive outcomes of discoveries and preliminary trials for treatments, and with that has come a surge of new investment into next generation therapeutics. It is these next generation therapeutics that are likely to herald the future successes of the field.
“The programme will draw together key themes within IO and tackle some of the common challenges faced, where participants will be able to learn directly from the experiences of prominent speakers and key opinion leaders. The agenda will include discussions on areas of development and clinical application which hold the most promise for creating the novel and effective immuno-oncological therapies of the future. It will also cover issues surrounding research and ethics within immuno-oncology.
“Building on the early successes in the field, I am particularly looking forward to hearing about the many innovative approaches being taken to improve patient outcomes further. At the forefront of these are: applications of bi-specific molecules to increase efficacy and therapeutic index compared to conventional antibodies; the engineering of highly potent and selective CAR-T cells; combinations of immuno-oncology agents with antibody drug conjugate; further development of cancer vaccines; and a multitude of combination approaches.”
The full letter of invitation is now available on the event website, where the latest brochure, speaker-line up and other exclusive content is available to download. Register your place for the conference, and accompanying workshops taking place on the 25th September at:
About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk